Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
在一項針對2期動量肥胖試驗的67名受試者的核磁共振成像子研究中，其中50人接受了48周的pemviduTide治療，瘦肉損失率（定義爲瘦肉質量與總質量變化相比的變化）爲21.9％。
Lean mass preservation was greater in subjects aged 60 years and older, in whom the lean loss ratio was only 19.9%. In addition to lean mass preservation, there was a preferential reduction of VAT, the adipose tissue associated with cardiovascular risk.
60歲及以上的受試者的精益質量保存率更高，其精益損失率僅爲19.9％。除了瘦肉保鮮外，還優先降低與心血管風險相關的脂肪組織VaT。
At the 2.4mg dose of pemvidutide, VAT was reduced by 25.6% at Week 48 compared to a 20.1% loss in subcutaneous adipose tissue.
在2.4mg劑量的pemvidutide下，第48周的vAT降低了25.6％，而皮下脂肪組織損失了20.1％。
譯文內容由第三人軟體翻譯。